Pages that link to "Q34193607"

The following pages link to Substrate- and kinase-directed regulation of phosphorylation of a cGMP-binding phosphodiesterase by cGMP. (Q34193607):

Displaying 26 items.

• Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation (Q24530647) (← links)
• Cloning and characterization of a cAMP-specific phosphodiesterase (TbPDE2B) from Trypanosoma brucei (Q24536226) (← links)
• Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A (Q24676441) (← links)
• Cloning and characterization of two splice variants of human phosphodiesterase 11A (Q24676977) (← links)
• The C. elegans cGMP-dependent protein kinase EGL-4 regulates nociceptive behavioral sensitivity (Q27321293) (← links)
• Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A (Q28593446) (← links)
• PDE5 is converted to an activated state upon cGMP binding to the GAF A domain (Q28593893) (← links)
• The unexpected evolution of basic science studies about cyclic nucleotide action into a treatment for erectile dysfunction. (Q30361487) (← links)
• Role of Ser102 and Ser104 as regulators of cGMP hydrolysis by PDE5A (Q34231776) (← links)
• cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action (Q34244951) (← links)
• ABCD of the phosphodiesterase family: interaction and differential activity in COPD (Q34961511) (← links)
• Study of the affinity between the protein kinase PKA and peptide substrates derived from kemptide using molecular dynamics simulations and MM/GBSA. (Q35294145) (← links)
• Molecular mechanisms of the alterations in NMDA receptor-dependent long-term potentiation in hyperammonemia. (Q36355312) (← links)
• Involvement of Cyclic Guanosine Monophosphate-Dependent Protein Kinase I in Renal Antifibrotic Effects of Serelaxin (Q37083919) (← links)
• The cGMP-dependent protein kinase--gene, protein, and function (Q40852750) (← links)
• Activation of PDE2 and PDE5 by specific GAF ligands: delayed activation of PDE5. (Q41485148) (← links)
• Cyclic nucleotide phosphodiesterases in Drosophila melanogaster. (Q41889474) (← links)
• Real-time monitoring the spatiotemporal dynamics of intracellular cGMP in vascular smooth muscle cells (Q41983620) (← links)
• The catalytic subunit of protein kinase A triggers activation of the type V cyclic GMP-specific phosphodiesterase from guinea-pig lung (Q42221795) (← links)
• Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme (Q42581981) (← links)
• Long-term potentiation in hippocampus involves sequential activation of soluble guanylate cyclase, cGMP-dependent protein kinase, and cGMP-degrading phosphodiesterase. (Q44228507) (← links)
• cGMP-Prkg1 signaling and Pde5 inhibition shelter cochlear hair cells and hearing function (Q50431784) (← links)
• Prevention of PKG-1α Oxidation Suppresses Antihypertrophic/Antifibrotic Effects From PDE5 Inhibition but not sGC Stimulation. (Q54121051) (← links)
• Localization of angiotensin-II type 1(AT1) receptors on buffalo spermatozoa: AT1 receptor activation during capacitation triggers rise in cyclic AMP and calcium. (Q54383876) (← links)
• Nitric oxide protects PC12 cells from serum deprivation-induced apoptosis by cGMP-dependent inhibition of caspase signaling (Q78094837) (← links)
• Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure (Q90331231) (← links)